CD4 þ CD56 þ hematodermic neoplasms [1] [2] [3] have been variably referred to as blastic NK-cell lymphomas, 4 ,5 CD56 þ blastic tumors, 6 CD4 þ CD56 þ lineage-negative malignancies, 7 blastic type 2 dendritic cell leukemia, 8 and plasmacytoid dendritic cell leukemia/lymphoma. 9 CD4 þ CD56 þ hematodermic neoplasms are characterized by presentation as extranodal masses that are often cutaneous, with eventual leukemic dissemination and a clinically aggressive course. 8 A growing body of phenotypic and functional data argues that they represent the malignant counterparts to plasmacytoid dendritic cells, or their precursors. 2, [7] [8] [9] [10] [11] For example, tumors display near-uniform expression of CD4, CD123 and TCL1, HLA-DR and CD45RA which are features of non-neoplastic plasmacytoid dendritic cells at various stages of differentiation. 12, 13 CD4 þ CD56 þ hematodermic neoplasms also fail to express markers of other hematopoietic lineages such as surface or cytoplasmic CD3, CD11b, CD11c, CD13, CD14, myeloperoxidase, lysozyme, CD117, CD19, CD20, CD79a, and CD138. Unlike many CD56 þ NK-cell malignancies, Epstein-Barr virus infection has not been detected in CD4 þ CD56 þ hematodermic neoplasms.
The few reports of functional studies of cultured cells from CD4 þ CD56 þ hematodermic neoplasms indicate parallels with plasmacytoid dendritic cells, including the capacity to differentiate into compe-tent antigen presenting cells that express co-stimulatory molecules (eg CD80, CD86) and promote antigen-specific activation of T cells. 10 In one study, cultured CD4 þ CD56 þ hematodermic neoplasm cells produced interferon-a in response to viral challenge, 14 which is a central functional property of plasmacytoid dendritic cells. However, CD4 þ CD56 þ hematodermic neoplasms also demonstrate a degree of immunophenotypic heterogeneity and show patterns of disease recurrence suggesting multi-lineage potential. 15 For example, variable expression of CD2, CD7, CD33, CD36, and CD68 has been demonstrated and a subset of cases display terminal deoxynucleotidyl transferase (TdT) immunoreactivity. 1, 3, [16] [17] [18] Blood dendritic cell antigen-2 (BDCA-2) is a recently described cell-surface protein that is selectively expressed on plasmacytoid dendritic cells. 19 Primary amino-acid sequence homology suggests that BDCA-2 (CLEC4C, HECL, CD303) may act as a carbohydrate-binding protein of the C-type lectin family, although specific ligands have not been reported. 20 Downstream functions of BDCA-2 are still under investigation, although roles in regulating interferon-a production and antigen uptake have been proposed based on studies employing ligating antibody as a surrogate ligand. 20 Several investigators have detected BDCA-2 expression in leukemic CD4 þ CD56 þ hematodermic neoplasms by flow cytometric studies, principally using the mouse monoclonal anti-BDCA-2, clone AC144. 8, 10, [21] [22] [23] BDCA-2 expression in infiltrating CD4 þ CD56 þ hematodermic neoplasms is not well characterized, largely due to lack of appropriate reagents for use in archived tissue sections.
We report here the production and characterization of rabbit polyclonal antibodies that can selectively detect BDCA-2 in fixed tissue specimens. We show that CD4 þ CD56 þ hematodermic neoplasms display variable expression of BDCA-2, in an inverse pattern with expression of TdT. Interestingly, clinical correlation data suggest that immunoreactivity for BDCA-2 may indicate a foreshortened survival. These data support a model in which CD4 þ CD56 þ hematodermic neoplasms represent transformation that recapitulates different stages of plasmacytoid dendritic cell maturation and manifest different biological potentials.
Materials and methods

Antibodies
Rabbit anti-sera were raised against a synthetic peptide containing the short cytoplasmic domain of BDCA-2 (amino acids 1-20; Cocalico Biologicals). The peptide was synthesized using standard fMOC chemistry with mass spectroscopy sequence confirmation (Global Peptide Services). Specific antipeptide antibodies (anti-cytoBDCA-2) were purified by peptide affinity chromatography using the SulfoLink kit (Pierce Chemical Co). Other antibodies included mouse monoclonal antibodies directed against BDCA-2 (AC144, Miltenyi Biotec, Auburn, CA, USA), CD2 (AB75, Novocastra, Newcastleupon-Tyne, UK), CD7 (CBC.27, DakoCytomation), CD45RA (4KB5, DakoCytomation, Carpinteria, CA, USA), CD123 (6H6, eBioscience, San Diego, CA, USA (11)), TCL1, 11 and TdT (SEN28, Novocastra, Birmingham, UK).
Cloning and Expression of Human BDCA-2
A donor apheresis product was obtained from a healthy volunteer using an institutionally approved protocol. Plasmacytoid dendritic cells, totaling 5 Â 10 6 were isolated using the MACS separation and monoclonal anti-BDCA-2 (Miltenyi Biotec). RNA was purified 24 followed by reverse transcription using the gene specific oligonucleotide primer, BDCA-2-R (5 0 -CTCGAGTATG TAGATCTTCT TCATCTT-3 0 ). Specific PCR employed primers BDCA-2-F (5 0 -CATATGGTGC CTGAAGAAGA GC-3 0 ) and BDCA-2-R. DNA sequencing confirmed the correct full-length coding region, 20 which was subcloned into the mammalian expression vector pcDNA3.1 þ (Invitrogen) to generate pFL.BDCA-2. After transfection of pFL.BDCA-2 into 293T cells, surface expression was confirmed by flow cytometry using PE-labeled monoclonal anti-BDCA-2 (Miltenyi Biotec).
Immunoprecipitation
Immunoprecipitations of Triton X-100 detergent extracts cells were performed using monoclonal anti-BDCA-2 (AC144) or control IgG and protein A beads as described. 20 Precipitated material underwent sodium dodecyl sulfate (SDS)-PAGE and transfer for immunoblot detection with anti-cyto-BDCA-2.
Immunoblotting
Cells and control cells were extracted into reducing SDS-sample buffer for immunoblotting. 25 SDS cell extracts were subject to electrophoresis on 10% reducing SDS polyacrylamide gels followed by transfer to nitrocellulose filters. After blocking, filters were probed with anti-cyto BDCA-2 (1:200). Bound antibodies were detected with horseradish peroxidase -conjugated goat anti-rabbit IgG (Jackson Labs) and ECL substrate (Pierce Chemical Co.) for detection with X-ray film.
Human Tissue Samples
Sections of formalin-fixed, paraffin-embedded tissues were drawn from the archives of the MD Anderson Cancer Center, the Emory University Available patient survival data were analyzed by the Kaplan Meier method and comparisons were made using the log-rank test. 26 P-values were 2-sided and a value o0.01 was accepted as significant.
Immunostaining
For immunofluorescence studies, cryostat sections were fixed, permeablized and blocked as previously. 27 Co-staining utilized rabbit anti-cytoBD-CA-2 (1:200) and mouse anti-BDCA-2 (1:10). Bound antibodies were detected with anti-rabbit IgG Alexa-568 and anti-mouse IgG Alexa-488. Nuclei were counter-stained with Topro-3-iodide according to manufacturer's instructions (Molecular Probes). Sections were mounted and cover slipped for viewing by immunofluorescence confocal microscopy using a Â 63 objective as detailed previously. 25, 27 For immunohistochemical analysis, formalinfixed, paraffin-embedded tissue sections underwent deparaffinization and rehydration followed by antigen unmasking in 100 mM Tris buffer, pH 10. 28 For single antibody labeling experiments, after blocking, primary antibodies, including anti-cyto BDCA-2 (1:50), anti-CD123 (1:300), and anti-CD3 (1:5), were separately applied. Detection of primary antibodies with the LSAB þ System for immunoperoxidase staining and standard DAB reaction followed the manufacturer's recommendations (DakoCytomation). In separate experiments, sections were costained with rabbit anti-cyto BDCA-2 (1:50) and mouse anti-TdT (1:50) as primary antibodies. The Envision Doublestain system (DakoCytomation) was employed to detect bound primaries with standard DAB and fast-red reactions. Sections were counterstained with hematoxylin before mounting for microscopy.
Staining was graded semi-quantitatively. For CD7, CD45RA CD123, TCL1, immunoreactivity was graded as 0 (negative), 1 þ (weak), or þ 2 (strong). For TdT and BDCA-2, immunoreactivity was graded on the proportion of immunoreactive tumor cells as 0 (none), 1 þ (up to 5%), 2 þ (up to 25%), 3 þ (25-50%) or uniform, strong expression (4 þ ).
Results
Specificity of Cyto-BDCA-2 Antibodies
To determine whether CD4 þ CD56 þ hematodermic neoplasms express BDCA-2, we generated antibodies against a synthetic peptide representing the predicted short amino-terminal cytoplasmic domain of BDCA-2. Biochemical specificity was first assessed in immunoprecipitation and immunoblotting experiments. BDCA-2 was immunoprecipitated from detergent cell extracts using the commercial specific anti-BDCA-2 monoclonal antibody (AC144) as previously described by Dzionek et al 20 Immunoprecipitates underwent SDS-PAGE and immunoblotting with cyto-BDCA-2 antibodies. Results in Figure 1a show a prominent band of the expected B37 kDa apparent molecular weight 20 detected by the cyto-BDCA-2 antibody in the specific BDCA-2 immunopreciptate, but not in the control. Bands in the control lane (CTL IP) are consistent with cross reactivity of the secondary anti-immunoglobulin detection reagent with antibody used for immunoprecipitation. SDS extracts of human 293T cell transfectants expressing full-length BDCA-2, control mock transfectant 293T cells and control adherent cell lines T-84 and CaCo2 underwent SDS-PAGE and transfer to nitrocellulose filters. As shown in Figure  1B , probing the filter with the cyto-BDCA-2 antibodies yielded a single broad band of B37 kDa only for cells transfected with BDCA-2. Negligible background binding to control cell extracts Using these antibodies, we assessed the expression of BDCA-2 in hyperplastic tonsils where plasmacytoid dendritic cells are abundant. 20 Detection of plasmacytoid dendritic cells using immunofluorescence microscopy on cryostat sections was compared using cyto-BDCA-2 antibodies and the well characterized monoclonal anti-BDCA-2. Colocalized membrane staining of scattered dendritic cells was noted with both the monoclonal BDCA-2 antibody (Figure 2a , green) and the rabbit cyto-BDCA-2 antibodies (Figure 2b , red) in the same cells as indicated in the merged image (Figure 2c, yellow) . These immunoreactive cells were clustered in the paracortical regions as expected for plasmacytoid dendritic cells. 20, 29 Immunofluorescence costaining experiments for CD123 and cyto-BDCA-2 also demonstrated a similar pattern of overlapping immunoreactivity, except for added CD123 reactivity in endothelium (data not shown).
Similarly, formalin-fixed paraffin-embedded sections of tonsil were immunostained for cyto-BDCA-2 and CD123, a relatively selective marker for plasmacytoid dendritic cells in lymphoid tissue sections.
11,30,31 BDCA-2 immunoreactivity was noted in clusters of cells adjacent to germinal centers ( Figure  2d ) that overlapped with anti-CD123 staining patterns (Figure 2e) , and was concentrated in the CD3 þ T-cell-rich interfollicular areas ( Figure 2F ) where plasmacytoid dendritic cells are most abundant. 11, 20, [30] [31] [32] Therefore, cyto-BDCA-2 antibodies allow selective plasmacytoid dendritic cell staining in formalin-fixed, paraffin-embedded and fresh tissues.
BDCA-2 is Expressed on a Subset of CD4 þ CD56 þ Hematodermic Neoplasms
We assessed BDCA-2 expression in 19 wellcharacterized patient cases of CD4 þ CD56 þ hematodermic neoplasms in formalin-fixed, paraffinembedded sections including 20 specimens (Table  1) and compared them to 6 true NK-cell neoplasms. Tissue sites assessed were skin (n ¼ 10), lymph node (n ¼ 4), larynx (n ¼ 1) and formalin-fixed, paraffinembedded bone marrow cores or clot sections (n ¼ 5). Ten patients showed expression of BDCA-2 in at least 5% of tumor cells. Figures 3a (case 9) and Figure 3b (case 1) typify the expected membrane pattern of BDCA-2 immunoreactivity on tumor cells. Nine cases of CD4 þ CD56 þ hematodermic neoplasms were negative for BDCA-2, as were six CD56 þ lymphomas of other types (4 EBV þ nasaltype NK lymphomas (Figure 3c ), 1 aggressive NK leukemia, 1 NK-like T-cell lymphoma). Figure 2 Reactivity of cyto-BDCA-2 antibodies with plasmacytoid dendritic cells. Confocal microscopy of cryostat sections of chronically inflamed, hyperplasic tonsil stained with the anti-BDCA-2 monoclonal antibody (a, green) and rabbit cyto-BDCA-2 antibodies (b, red). In (c), merged images display sites of co-labeling (yellow); nuclei are highlighted with Topro-3-iodide (blue). Immunohistochemical staining was performed on serial sections of formalin-fixed, paraffin-embedded human tonsil using cyto-BDCA-2 antibodies (d), anti-CD123 (e) and anti-CD3 (f). Germinal centers are indicated with red asterisks (*). Original magnifications Â 100.
We assessed whether statistically significant correlations (Po0.02) existed between BDCA-2 expression and others markers of CD4 þ CD56 þ hematodermic neoplasms. BDCA-2 immunoreactivity correlated negatively with TdT expression (corrected Spearman rank correlation r ¼ À0.68). Figure 3 Reactivity of cyto-BDCA-2 antibodies with CD4 þ CD56 þ hematodermic neoplasm. Immunohistochemical staining of formalinfixed, paraffin-embedded sections of tumors using the anti-cyto BDCA-2 antibodies including CD4 þ CD56 þ hematodermic neoplasms (a, case 9; b, case 1) and a CD56 þ nasal type NK/T cell lymphoma (c); original magnification Â 600 (a, c, and insets a-c) Â 20 (b). Dual immunostaining of three cases of CD4 þ CD56 þ hematodermic neoplasm, specified in the text, with cyto-BDCA-2 antibodies (brown) and an anti-TdT antibody (red); original magnifications Â 600.
BDCA-2 in CD4 þ CD56 þ hematodermic neoplasms DL Jaye et al By contrast, BDCA-2 and CD7 expression were positively correlated (corrected Spearman rank correlation r ¼ 0.61) for the 14 cases scored. Indeed, in case 7, we observed loss of both CD7 and BDCA-2 reactivity upon tumor recurrence. Double-immunostaining with BDCA-2 and TdT yielded similar results to those of individual stains as exemplified by results in Figure 3d -f. In Figure 3d , strong BDCA-2 immunoreactivity is accompanied by negligible TdT reactivity (case 5), whereas a tumor manifesting intense TdT nuclear reactivity shows a paucity of anti-BDCA-2 reactivity in Figure 3f (case 18) . A case displaying intermediate staining for both TdT and BDCA-2 is presented in Figure 3e (case 7) . No correlations were apparent between BDCA-2 immunoreactivity and level of expression of CD2, CD123, TCL1, or the site of biopsy, tumor cell size, and nuclear features (ie blastoid/fine chromatin versus presence of prominent nucleoli).
Lastly, we asked if there were survival differences that correlate with BDCA-2 immunoreactivity. The follow-up data available for 12/19 cases are shown in Table 1 and include the length of follow-up and status at that time as categorized as either complete remission, alive with disease, or dead of disease. Follow-up time ranged from 90 to 2082 days. Kaplan Meier survival curves displayed in Figure 4 demonstrate statistically significant differences in overall survival (upper panel) and disease-free survival (lower panel) between the BDCA-2 positive and negative groups. Median overall survival and disease-free survival were approximately 1160 days for the BDCA-2 negative group. By contrast, median overall survival and disease-free survival were merely 450 days and 360 days, respectively, for the BDCA-2 positive cases.
Discussion
Here, we show that the plasmacytoid dendritic cellselective marker BDCA-2 is detectable in approximately 50% of formalin-fixed CD4 þ CD56 þ hematodermic neoplasms, using a new antibody reagent. These results support the previous findings of BDCA-2 detected by flow cytometry in the leukemic phase of hematodermic neoplasms 8, 10, [21] [22] [23] and by frozen section immunostaining in very small number of cases. 33 Our data suggest a greater degree of heterogeneity of expression in hematodermic neoplasms in tissues. Given the decreased sensitivity of detection for most epitopes in formalin-fixed tissues, it is not possible to be certain if BDCA-2 expression is below the limits of detection or completely negative in many cases. Nonetheless, the result adds to the growing number of observations suggesting that CD4 þ CD56 þ hematodermic neoplasms are an entity with considerable immunophenotypic and functional plasticity. Indeed, some CD4 þ CD56 þ hematodermic neoplasms recur following treatment as tumors with unequivocal monocytic or myelomonocytic differentiation. 15 Our novel observation that there is an inverse correlation between TdT and BDCA-2 expression suggests a model for understanding this plasticity. In non-neoplastic plasmacytoid dendritic cells, BDCA-2 is regulated as a maturation marker, with increased expression as plasmacytoid dendritic cell precursors mature and differentiate in the bone marrow and blood. Flow cytometric analysis of bone marrow by Dzionek et al 34 argues that cell surface BDCA-2 increases incrementally as plasmacytoid dendritic cells differentiate from CD34 þ precursors. Thus, the BDCA-2-positive subset of CD4 þ CD56 þ hematodermic neoplasms may represent a tumor recapitulating a more mature plasmacytoid dendritic cell stage and conversely, the TdT þ subset may represent a less mature, precursor plasmacytoid dendritic cell leukemia/lymphoma. Interestingly, expression of BDCA-2 and CD7 on plasmacytoid dendritic cells appears independently to identify stages of differentiation manifesting distinct immunologic capacities. 13, 19 If this paradigm applies as well to CD4 þ CD56 þ hematodermic neoplasms, the BDCA-2/CD7 positive and negative subsets may similarly reflect functional plasticity that could impact biologic BDCA-2 in CD4 þ CD56 þ hematodermic neoplasms DL Jaye et al behavior. The survival data presented, though of limited scope, are consistent with this possibility, suggesting that BDCA-2 immunoreactivity, as demonstrated here, may impart significantly worse overall and disease-free survivals for cases of CD4 þ CD56 þ hematodermic neoplasms. In accord with our results, Bekkenk et al 17 analyzed a series of 63 blastic NK cell lymphomas, including cases taken from the literature, and reported that TdT expression served as an independent positive prognostic factor.
How might the BDCA-2-positive, TdT-negative phenotype confer a worse prognosis for CD4 þ CD56 þ hematodermic neoplasms than the converse BDCA-2-negative, TdT-positive phenotype? One reason for the worse prognosis of the BDCA-2-positive subset may simply relate to potential for reduced response to therapies, which are often mixed acute myeloid leukemia and acute lymphoblastic lymphoma regimens. For example, such reduced response by 'more mature' BDCA-2-positive, TdT-negative tumors might reflect a marginally lower growth fraction compared to the TdT-positive subset. A more interesting speculation may be drawn from observations of Chaperot et al 10 who demonstrated that cultured leukemic cells of CD4 þ CD56 þ hematodermic neoplasms can manifest plasmacytoid dendritic cell-like immunologic properties, including upregulation of costimulatory molecules and antigen presentation to T cells. The ability of BDCA-2 expressing plasmacytoid dendritic cells to induce Th2 immunity and the association of donor plasmacytoid dendritic cells with decreased allo-reactivity of donor T-cells after allogeneic bone marrow transplantation 26 suggest the hypothesis that the CD4 þ CD56 þ malignant counterpart of plasmacytoid dendritic cell may have capacity for antigen presentation and ability to induce Th2 and anergic immune responses in vivo. In short, these properties could yield decreased antitumor immune responses in patients with BDCA-2-positive, TdT-negative 'more mature' tumors that are induced by the tumor itself. By contrast, 'less mature', BDCA-2-negative, Tdt-positive tumors may represent neoplasms that, like early precursors of plasmacytoid dendritic cells, are significantly less potent at modifying immune responses, and thus more susceptible to anti-tumor immune activity. In future studies, it will be important to corroborate and expand the findings reported here and to determine if these antigen expression patterns are stable over the course of disease and whether and how functional plasticity in CD4 þ CD56 þ hematodermic neoplasms may impact biologic behavior and prognosis. The new BDCA-2 reagent reported here will likely aid in these endeavors.
